Adage Capital Partners Gp, L.L.C. Tarsus Pharmaceuticals, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $56.4 Billion
- Q2 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 543,000 shares of TARS stock, worth $36.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
543,000
Previous 510,000
6.47%
Holding current value
$36.8 Million
Previous $26.2 Million
16.04%
% of portfolio
0.04%
Previous 0.05%
Shares
2 transactions
Others Institutions Holding TARS
# of Institutions
215Shares Held
46.3MCall Options Held
7.8KPut Options Held
0-
Black Rock Inc. New York, NY3.27MShares$221 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.11MShares$211 Million1.94% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.98MShares$202 Million5.63% of portfolio
-
Jennison Associates LLC2.47MShares$167 Million0.06% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$166 Million5.96% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.81B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...